ArticleGland surgery2024

Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.

Guolin Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.